Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
24 January 2019 | Story Lacea Loader | Photo Sonia Small
Dr Engela van Staden
Dr Engela van Staden started as Vice-Rector: Academic on 1 January 2019.
The Executive Committee of the Council (on behalf of Council) of the University of the Free State (UFS) approved the appointment of Dr Engela van Staden as Vice-Rector: Academic during a meeting held on 5 December 2018. She started on 1 January 2019 as Vice-Rector: Academic (designate) and will take up the position from 1 February 2019 as Vice-Rector:  Academic. Prof Hendri Kroukamp, who acted in the position of Vice-Rector: Academic, will resume his portfolio as Dean: Faculty of Economic and Management Sciences on 1 February 2019. 

“Dr Van Staden has an immense knowledge of the higher-education system, governance, planning, and policy frameworks within the sector, and of enrolment planning and management, and will provide leadership within this domain. She has been in senior management positions at faculty, institutional, and national level for a period of 20 years and is one of the experts in academic-programme development and curriculum design in the country. I look forward to working with her and welcoming her to the university,” says Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.
 
Dr Van Staden holds a DPhil in Education from the Rand Afrikaans University (now University of Johannesburg). She was Deputy Vice-Chancellor: Teaching, Learning and Community Engagement at the Sefako Makgatho Health Sciences University. Prior to this she was, among others, Chief Director: University Academic Planning and Management Support at the Department of Higher Education and Training (DHET) from 2009 to 2017, Director: Strategic Management Support at Tshwane University of Technology from 2004 to 2009, Dean: Faculty of Education and Director: Strategic Planning at the then Technikon Northern Gauteng from 1996 to 2003. 
 
Her responsibilities at the Sefako Makgatho Health Sciences University included teaching and learning, quality assurance, strategic and academic planning, technology and education innovation, planning and reporting for and on earmarked and development grants, curriculum reviews, infrastructure planning, blended learning, and the redesign of the university’s business model.
 
In the portfolio of Chief Director: University Academic Planning and Management Support at the DHET, she was responsible for, among others, the national enrolment targets of 2013 and 2019, and institutional performance targets aligned to the Minister’s performance targets, the management and approval of all national programme applications, the development of the distance policy for universities / open learning strategy, the monitoring of universities under administration, the Medium Term Expenditure Framework (MTEF) budget allocations to universities, the planning and establishing of new universities in Mpumalanga and Northern Cape with specific reference to the academic programmes and governance and policy environment, and the establishment of the Central Application System (CAS) and Service and Clearing House Mechanism (CACH), which includes a project management office, business architecture and the formulation of proposals towards the governance and management of such a function.
 
She has supervised master’s and doctoral students, authored and co-authored a number of academic articles, compiled a vast array of technical reports, and participated in a wide variety of national and international projects in South Africa and abroad.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept